

Nicox: Half-year liquidity contract statement with Kepler Cheuvreux

July 11, 2023 – release at 7:30 am CET
Sophia Antipolis, France

Under the liquidity contract entered into between Nicox and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30, 2023:

- 304,567 shares
- € 10,640.56

- Number of executions on buy side on semester: 128
- Number of executions on sell side on semester: 111
- Traded volume on buy side on semester: 74,584 shares for € 62,919.32
- Traded volume on sell side on semester: 58,982 shares for € 51,368.57

As a reminder:

- The following resources appeared on the last half year statement on December 31, 2022 on the liquidity account:
 - 288,965 shares
 - € 22,074.60

 - Number of executions on buy side on semester: 274
 - Number of executions on sell side on semester: 195
 - Traded volume on buy side on semester: 155,703 shares for € 262,378.38
 - Traded volume on sell side on semester: 100,347 shares for € 178,155.02

- The following resources appeared on the liquidity account when the activity started:
 - 0 shares
 - € 500,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

	Buy Side		
	Number of executions	Number of shares	Traded volume in EUR
Total	128	74 584	62 919.32
02/01/2023	-	-	-
03/01/2023	-	-	-
04/01/2023	1	1 000	1 140.00
06/01/2023	2	2 000	2 220.00
09/01/2023	-	-	-
10/01/2023	1	1 000	1 100.00
11/01/2023	-	-	-
12/01/2023	1	1 000	1 100.00
13/01/2023	1	1 000	1 120.00
16/01/2023	3	1 500	1 665.00
17/01/2023	1	1 000	1 100.00
18/01/2023	4	2 000	2 200.00
19/01/2023	3	2 000	2 180.00
20/01/2023	3	2 001	2 141.07
23/01/2023	7	2 999	3 148.95
25/01/2023	6	4 000	3 920.00
26/01/2023	-	-	-
27/01/2023	6	4 000	3 920.00
30/01/2023	2	1 500	1 485.00
31/01/2023	1	500	495.00
01/02/2023	1	1 000	990.00
02/02/2023	2	1 500	1 470.00
03/02/2023	1	1 000	960.00
06/02/2023	3	1 500	1 410.00
07/02/2023	1	1 000	930.00
08/02/2023	1	500	460.00
09/02/2023	2	1 000	900.00
13/02/2023	-	-	-
14/02/2023	1	1 000	890.00
15/02/2023	1	1 000	880.00
17/02/2023	1	500	430.00
20/02/2023	1	50	43.00
23/02/2023	1	50	42.50
24/02/2023	2	1 020	846.60
27/02/2023	5	1 900	1 558.00
28/02/2023	1	500	400.00
01/03/2023	3	1 964	1 571.20
02/03/2023	2	1 000	800.00
03/03/2023	-	-	-
06/03/2023	1	1 000	790.00
07/03/2023	2	1 500	1 185.00
08/03/2023	4	1 500	1 185.00

	Sell Side		
	Number of executions	Number of shares	Traded volume in EUR
Total	128	74 584	62 919.32
02/01/2023	4	2 170	2 517.20
03/01/2023	5	957	1 119.69
04/01/2023	1	1	1.18
06/01/2023	-	-	-
09/01/2023	1	1	1.14
10/01/2023	-	-	-
11/01/2023	6	2 000	2 220.00
12/01/2023	13	5 606	6 390.84
13/01/2023	3	938	1 069.32
16/01/2023	1	1 000	1 130.00
17/01/2023	-	-	-
18/01/2023	1	2 000	2 240.00
19/01/2023	-	-	-
20/01/2023	-	-	-
23/01/2023	-	-	-
25/01/2023	-	-	-
26/01/2023	2	2 005	2 005.00
27/01/2023	4	2 000	2 040.00
30/01/2023	-	-	-
31/01/2023	-	-	-
01/02/2023	-	-	-
02/02/2023	-	-	-
03/02/2023	-	-	-
06/02/2023	-	-	-
07/02/2023	-	-	-
08/02/2023	-	-	-
09/02/2023	-	-	-
13/02/2023	7	4 000	3 600.00
14/02/2023	-	-	-
15/02/2023	-	-	-
17/02/2023	1	100	87.00
20/02/2023	4	4 900	4 263.00
23/02/2023	-	-	-
24/02/2023	-	-	-
27/02/2023	-	-	-
28/02/2023	4	2 000	1 640.00
01/03/2023	1	2 000	1 620.00
02/03/2023	-	-	-
03/03/2023	2	504	403.20
06/03/2023	-	-	-
07/03/2023	-	-	-
08/03/2023	-	-	-

	Buy Side		
	Number of executions	Number of shares	Traded volume in EUR
Total	128	74 584	62 919.32
09/03/2023	2	1 000	780.00
10/03/2023	2	500	380.00
13/03/2023	1	500	375.00
15/03/2023	1	500	350.00
17/03/2023	1	300	198.00
20/03/2023	1	200	128.00
21/03/2023	-	-	-
29/03/2023	1	300	180.00
14/04/2023	-	-	-
17/04/2023	5	1 800	1 260.00
18/04/2023	-	-	-
19/04/2023	9	4 000	2 520.00
20/04/2023	2	1 300	767.00
21/04/2023	3	1 000	580.00
25/04/2023	2	1 000	550.00
26/04/2023	-	-	-
02/05/2023	-	-	-
04/05/2023	1	300	180.00
09/05/2023	1	1 000	580.00
10/05/2023	3	2 500	1 475.00
12/05/2023	1	1 000	590.00
15/05/2023	1	1 000	600.00
16/05/2023	2	2 000	1 160.00
17/05/2023	-	-	-
25/05/2023	2	2 000	1 160.00
29/05/2023	5	3 000	1 710.00
01/06/2023	-	-	-
06/06/2023	1	300	165.00
20/06/2023	1	500	255.00
21/06/2023	2	600	300.00

	Sell Side		
	Number of executions	Number of shares	Traded volume in EUR
	128	74 584	62 919.32
	-	-	-
	-	-	-
	-	-	-
	-	-	-
	-	-	-
	1	77	50.82
	1	123	81.18
	-	-	-
	25	12 800	10 368.00
	-	-	-
	3	600	438.00
	-	-	-
	-	-	-
	-	-	-
	9	4 200	2 688.00
	2	500	325.00
	-	-	-
	2	4 000	2 400.00
	-	-	-
	3	2 000	1 200.00
	-	-	-
	-	-	-
	4	2 000	1 180.00
	-	-	-
	-	-	-
	1	500	290.00
	-	-	-
	-	-	-
	-	-	-

About Nicox

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel nitric oxide-donating bimatoprost, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also conducting research on NCX 1728, a nitric oxide-donating phosphodiesterase 5 inhibitor, in retinal conditions. NCX 4251, a novel, patented, ophthalmic suspension of fluticasone propionate nanocrystals for topical ocular application for dry eye disease, is being developed by Ocumension Therapeutics in China under an exclusive license agreement and is available for partnering elsewhere. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIAE® in allergic conjunctivitis, licensed in multiple geographies, including to EyeVance Pharmaceuticals, LLC (a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd.), in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

www.nicox.com

Analyst coverage

Bryan, Garnier & Co	Eric Yoo	Paris, France
Edison Investment Research	Pooya Hemami	London, UK
H.C. Wainwright & Co	Yi Chen	New York, U.S.
Kepler Cheuvreux	Arsene Guekam	Paris, France



The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contacts

Nicox

Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com

Forward-Looking Statements

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in section 2.7 of the 'Rapport Annuel 2022' which is available on Nicox's website (www.nicox.com).

Nicox SA

Drakkar 2 - Bât D
2405 route des Dolines
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99